L

Lavipharm SA
ATHEX:LAVI

Watchlist Manager
Lavipharm SA
ATHEX:LAVI
Watchlist
Price: 0.975 EUR -1.12%
Market Cap: 164.5m EUR
Section:
 

Relative Value

The Relative Value of one LAVI stock under the Base Case scenario is 0.888 EUR. Compared to the current market price of 0.975 EUR, Lavipharm SA is Overvalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LAVI Relative Value
Base Case
0.888 EUR
Overvaluation 9%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

3.1
P/S
P/S
Price to Sales
3.1
vs History
1
vs Industry
54
Median 3Y
2.5
Median 5Y
1.7
Industry
2.7
More Details
42.6
P/E
P/E
Price to Earnings
42.6
vs History
28
vs Industry
32
Median 3Y
42.3
Median 5Y
16.3
Industry
21.6
More Details
117.2
P/OCF
P/OCF
Price to OCF
117.2
vs History
9
vs Industry
7
Median 3Y
50.8
Median 5Y
28.9
Industry
16.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-13.2
Median 5Y
-18.9
Industry
22.9
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
11
vs Industry
27
Median 3Y
2.6
Median 5Y
2.3
Industry
2.3
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
0
vs Industry
50
Median 3Y
2.9
Median 5Y
1.8
Industry
3
More Details
7.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.3
vs History
3
vs Industry
44
Median 3Y
6.2
Median 5Y
4.3
Industry
5.6
More Details
16.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.7
vs History
12
vs Industry
29
Median 3Y
14.9
Median 5Y
11.4
Industry
13.4
More Details
30.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
30.1
vs History
11
vs Industry
23
Median 3Y
26
Median 5Y
16.3
Industry
16.7
More Details
132.1
EV/OCF
EV/OCF
Enterprise Value to OCF
132.1
vs History
9
vs Industry
6
Median 3Y
57.7
Median 5Y
33.5
Industry
16.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-29
Median 5Y
-3.5
Industry
18.9
More Details
2
EV/IC
EV/IC
Enterprise Value to IC
2
vs History
9
vs Industry
37
Median 3Y
1.7
Median 5Y
1.7
Industry
2
More Details

Multiples Across Competitors

LAVI Competitors Multiples
Lavipharm SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
GR
Lavipharm SA
ATHEX:LAVI
164.5m EUR 3.1 42.6 16.7 30.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.5B CHF 4.4 28.8 12.3 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.9 159.4
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.4B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.4 11.4 13.3
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
GR
L
Lavipharm SA
ATHEX:LAVI
Average P/E: 26.8
42.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.4
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
GR
L
Lavipharm SA
ATHEX:LAVI
Average EV/EBITDA: 401.5
16.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
GR
L
Lavipharm SA
ATHEX:LAVI
Average EV/EBIT: 1 715.1
30.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
LAVI intrinsic value, competitors valuation, and company profile.
DCF Valuation
LAVI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LAVI stock valuation using valuation multiples.
Wall Street Estimates
LAVI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LAVI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.